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 The increasing awareness of the importance of the proper maternal thyroid function for fetal development 
prompted the development of guidelines on thyroid diseases in pregnancy. They have been created based on trial 
results as well as the personal experience of experts. 
The main differences between guidelines published by the Endocrine Society (ES, 2007, revised in 2012), the 
American Thyroid Association (ATA, 2011) and the Polish Society of Endocrinology (PSE, 2011) are further 
discussed. It has to be mentioned that other national guidelines also exist. 
Physiological changes in thyroid function during gestation influence test results, making the application of general 
population thyroid hormones reference values for pregnant women the most controversial. Commercially available 
free thyroid hormones assays tend to give values lower than the actual ones, particularly during the 3rd trimester of 
pregnancy. The Endocrine Society stresses a need to establish the trimester-specific reference values for each 
laboratory, however, the American Thyroid Association defines TSH reference values of 0.1-2.5, 0.2-3.0, and 
0.3-0.3 µIU/ml for the 1st, 2nd and 3rd trimester of pregnancy, respectively, if such site-specific TSH reference is 
not available. The results of a multi-centre study on thyroid hormone reference values for Polish pregnant women 
are in press. 
In pregnancy, there is an approximately 50% increase in daily iodine requirement. All societies recommend daily 
iodine intake of 250 μg during pregnancy and lactation, which should be obtained by additional supplementation 
with formulas containing 150 μg of iodine. 
The endocrine societies are concerned with careful management of both overt and subclinical hypothyroidism in 
pregnant women and in women of childbearing age, especially because the number of such cases has increased 
significantly during the last decade. Moderate-to severe maternal hypothyreosis is associated with maternal and 
fetal adverse outcomes. The endocrine societies agree that a dose of L-thyroxin has to be adjusted to maintain TSH 
level within the trimester-specific reference range. A pregnant woman should be followed with TSH measurements 
every 4-6 weeks. ATA strongly recommends against therapy other than L-thyroxin preparations, including T3. 
After delivery L-thyroxin should be reduced to the pre-conception dose (ATA, ES, PSE) and TSH checked 4-6 
weeks postponed. Consequences of mild maternal hypothyroidism, as well as the level of TSH requiring 
intervention, are still a matter of debate. According to current guidelines, TSH levels in hypothyroid women of 
childbearing age should be maintained below 2,5 µIU/ml to reduce the risk of TSH increase in early pregnancy. 
There is no need to monitor of the thyroid function in foetuses and newborns of hypothyroid mothers (ATA) – in 
Polish newborns a congenital hypothyroidism screening with TSH is routinely performed. Some issues are still 
debated, i.e. the necessity to treat isolated hypothyroxinemia during pregnancy or L-thyroxin administration in 
women with normal thyroid function and positive anti-thyroid antibodies. The lack of unequivocal data supporting 
the treatment of such cases during pregnancy is also stressed by the PSE. 
The differences in management of hyperthyroidism during pregnancy mainly concern the use of anti-thyroid drugs: 
according to the ATA propylothiouracyl (PTU) should be used during the first trimester and patients treated with 
methimazole (MMI) should be switched to PTU at the moment the pregnancy is confirmed; following the first 
trimester consideration should be given to switching to MMI. The Endocrine Society recommends the use of PTU 
as first line therapy in the first trimester as MMI is potentially responsible for congenital abnormalities; if PTU is 
not available or it is not tolerated MMI should be administered. Moreover, the ES states that decision which 
anti-thyroid drug is given should be also driven by the practitioners’ own experience. Monitoring of the liver 
function in patients treated with PTU is recommended by the ES only. 
The universal screening of asymptomatic pregnant women or women in childbearing age for thyroid dysfunction 
remains controversial. The ES guideline does not recommend the universal screening suggesting that aggressive 
case finding should be rather considered. However there was no agreement between all members of the Guideline 
Committee - some of them recommended screening of all pregnant women for serum TSH abnormalities by the 
ninth week of gestation or at the time of their first visit. The ATA does not recommend the universal screening. 
Routine TSH screening is recommended at the 4th-8th week of gestation (first prenatal visit) and in women 
planning pregnancy by the PSE. 
Screening for thyroid autoimmunity is not recommended but may be considered if appropriate, e.g. in recurrent 
spontaneous abortion or miscarriage. 
The frequency of nodular goitre in pregnant women is up to 20-30%, and differs between populations. The 
formation of new thyroid lesions during pregnancy is observed in 10-20% of women. The management of the 
nodular goitre in pregnancy does not differ from the general population (thyroid function assessment, a TPO in 
hypothyroid women, US and biopsy if needed). There are no essential differences in medullary and anaplastic 
thyroid cancer management in pregnant women. In case of differentiated thyroid cancer (DTC) the surgery can be 
performed after delivery as it is recommended by the ATA. If DTC is diagnosed before the 24th week of gestation 
– thyroid surgery should be considered before the end of the 2nd trimester, particularly for rapidly enlarging 
lesions (ES, PSE recommendation). If the patient is to be managed conservatively, L-thyroxin should be introduced 
to maintain the TSH level below 0.1 μIU/ml according to the PSE. The ATA recommends maintaining TSH values 
between 0.1-1.5 µIU/ml, and the ES – suppressed TSH and FT4 or total T4 in the upper normal range for 
pregnancy. 
Mothers with anti-TPO positivity are at increased risk of thyroid illness after pregnancy. The discussed guidelines 
differ slightly in screening indications for postpartum thyroiditis. The lack of evidence for anti-thyroid drug use in 
thyrotoxicosis phase is unquestionable. During hypothyreosis phase careful control is necessary and the treatment 
with l-thyroxin of all women planning next pregnancy is recommended. 
Summing up, it should be stressed that despite a huge progress which has been made in our understanding of 
thyroid physiology and pathology in pregnancy there are still important areas of uncertainty and further research is 
needed to optimize the management of thyroid diseases in pregnancy. The new version of the joint ATA and the 
ES guidelines is to be released in 2016. The Polish recommendations also need to be revised. 
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